AMPH Q3 2020 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$83M+4.1% YoY

Gross Profit

$37M43.8% margin

Operating Income

$4M4.2% margin

Net Income

$4M4.7% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

-2.8%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$3M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$614M

Total Liabilities

$163M

Stockholders' Equity

$405M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$80M	+4.1%
Gross Profit	$37M	$35M	+3.6%
Operating Income	$4M	$2M	+46.3%
Net Income	$4M	$1M	+199.2%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$2M100%

Geographic Segments

U

$79M98%

C

$2M2%